Tranexamic acid versus etamsylate in reducing blood loss in patients with high risk of postpartum hemorrhage
Phase 1
Completed
- Conditions
- post partum hemorrhage
- Registration Number
- PACTR202205750416982
- Lead Sponsor
- October 6th university and Ain shams Maternity hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 180
Inclusion Criteria
All pregnant women who will give birth vaginally, full term of gestation age, susceptible for post-partum hemorrhage as: • History of pervious postpartum hemorrhage
precipitate labour or instrumental delivery or
prolonged induction of labour.
•Anemic (hemoglobin between 8-10mg/dl),
diabetic, macrosomic baby
Exclusion Criteria
Women with thrombophilia, or coagulopathy cardiovascular, renal, or liver disorders; or contraindication to any drug used in the study protocol as (allergy to TXA or its excipients)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie tranexamic acid's antifibrinolytic effects in postpartum hemorrhage prevention?
How does tranexamic acid compare to etamsylate in reducing blood loss during normal vaginal delivery in high-risk patients?
Are there specific biomarkers that predict response to tranexamic acid or etamsylate in postpartum hemorrhage management?
What are the known adverse events associated with tranexamic acid versus etamsylate in obstetric populations?
What combination therapies or alternative antifibrinolytic agents show promise in postpartum hemorrhage prevention alongside tranexamic acid?